X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Mavorixafor is an investigational small-molecule antagonist of the CXCR4 receptor being developed as a once-daily oral therapy for WHIM syndrome and certain chronic neutropenic disorders.
Lead Product(s): Mavorixafor
Therapeutic Area: Immunology Product Name: X4P-001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
X4P-001 (mavorixafor) is an investigational small-molecule antagonist of CXCR4 being developed as a once-daily oral therapy to correct the dysfunction resulting from the underlying causes of WHIM.
Lead Product(s): Mavorixafor
Therapeutic Area: Immunology Product Name: X4P-001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2023
Details:
The financing will be used for the potential commercial launch of X4P-001 (mavorixafor) in individuals with WHIM syndrome and continue to advance mavorixafor for certain chronic neutropenic disorders.
Lead Product(s): Mavorixafor
Therapeutic Area: Rare Diseases and Disorders Product Name: X4P-001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hercules Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing August 03, 2023
Details:
X4 expects to use the proceedings for continued clinical development and commercial readiness of its lead candidate, X4P-001 (mavorixafor), an orally bioavailable CXCR4 antagonist.
Lead Product(s): Mavorixafor
Therapeutic Area: Immunology Product Name: X4P-001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: $65.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 16, 2023
Details:
X4P-001 (mavorixafor) is an investigational small-molecule antagonist of CXCR4 being developed as a once-daily oral therapy to correct the dysfunction resulting from the underlying causes of WHIM.
Lead Product(s): Mavorixafor
Therapeutic Area: Immunology Product Name: X4P-001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
X4P-001 (mavorixafor) is a small molecule antagonist of chemokine receptor CXCR4. Due to mavorixafor’s ability to antagonize CXCR4 and improve the mobilization of WBC, mavorixafor has the potential to provide therapeutic benefit across a variety of immune system diseases.
Lead Product(s): Mavorixafor
Therapeutic Area: Rare Diseases and Disorders Product Name: X4P-001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: $65.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 07, 2022
Details:
X4P-001 (mavorixafor), a small molecule antagonist of chemokine receptor CXCR4 is being developed as an oral, once-daily therapy. Mavorixafor has the ability to antagonize CXCR4 and improve the mobilization of white blood cells.
Lead Product(s): Mavorixafor
Therapeutic Area: Rare Diseases and Disorders Product Name: X4P-001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering December 06, 2022
Details:
Trial meets primary endpoint and first key secondary endpoint, with X4P-001 (mavorixafor) achieving statistically significant and clinically relevant longer times above threshold levels for both absolute neutrophil and absolute lymphocyte counts versus placebo.
Lead Product(s): Mavorixafor
Therapeutic Area: Genetic Disease Product Name: X4P-001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
Results of the Phase 1b clinical trial suggested that X4P-001 (mavorixafor) could be the first oral treatment for CN disorders and has the potential to reduce or replace injectable G-CSF, the current standard of care.
Lead Product(s): Mavorixafor
Therapeutic Area: Hematology Product Name: X4P-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2022
Details:
X4 expects to use these funds for continued clinical development and commercial readiness of its lead candidate, X4P-001 (mavorixafor), and for business development activities, working capital, and general corporate purposes.
Lead Product(s): Mavorixafor
Therapeutic Area: Immunology Product Name: X4P-001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: New Enterprise Associates
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 30, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
